What Does CJC-1295 Do? Human Results and Vial Tests
Two trials paid for by ConjuChem enrolled 66 healthy adults (PMID 16352683). One injection raised mean growth hormone twofold to tenfold for at least six days (PMID 16352683). It raised mean IGF-I 1.5-fold to threefold for 9 to 11 days (PMID 16352683). The trials tested the long-acting form called CJC-1295 with DAC. This form binds to albumin, a blood protein. They did not measure muscle gain, recovery, sleep, or fat loss. These claims were checked 21 August 2026.
What did CJC-1295 do in human studies?
The human findings come from two trial papers and one later study of stored samples. That later paper reused samples from one trial group. It did not test the drug in more people.
Two randomized trials in 66 healthy adults
Teichman and his team reported two trials with random group assignment. Both used a placebo control. Both were double-blind (PMID 16352683). Study 1 enrolled 42 people, with 35 assigned CJC-1295 and 7 assigned placebo (PMID 16352683). Study 2 enrolled 24 people, with 20 assigned CJC-1295 and 4 assigned placebo (PMID 16352683). The adults were 21 to 61 years old (PMID 16352683).
One injection raised mean growth hormone twofold to tenfold for at least six days (PMID 16352683). Mean IGF-I rose 1.5-fold to threefold for 9 to 11 days (PMID 16352683). The estimated half-life was 5.8 to 8.1 days (PMID 16352683). In the repeat-injection trial, mean IGF-I stayed above baseline for up to 28 days (PMID 16352683).
Funding: ConjuChem funded both trials. Three authors worked for ConjuChem. These facts and results were checked 21 August 2026.
Growth hormone pulses in 12 healthy men
Ionescu and Frohman studied 12 healthy men aged 20 to 34 (PMID 17018654). Each man gave samples through the night before the drug. He did so again one week after it. Mean growth hormone rose 46% (PMID 17018654). Trough growth hormone, measured between pulses, rose 7.5-fold (PMID 17018654). Mean IGF-I rose from 165 to 240 ng/mL, a reported 44% increase (PMID 17018654). The rate of growth hormone pulses did not change (PMID 17018654). Pulse size did not change (PMID 17018654).
Funding: ConjuChem partly funded the study. NIH General Clinical Research Center grant M01-RR-13987 also supported it. Frohman disclosed consulting for ConjuChem. These facts and results were checked 21 August 2026.
A later analysis reused samples from 11 of those men
A 2009 paper studied stored samples from 11 men in the Ionescu cohort (PMID 19386527). The team checked 192 protein spots one week after CJC-1295 (PMID 19386527). Five spots changed significantly (PMID 19386527). Two spots decreased. They represented an apolipoprotein A-I form and a transthyretin form. Three spots increased. They represented beta-hemoglobin, an albumin fragment, and a mixed immunoglobulin and albumin fragment. One change tracked with the IGF-I change, with r-squared 0.668 and p = 0.002 (PMID 19386527).
This paper adds protein measurements. It is not a new trial in a fresh group of men. It does not show a muscle, recovery, sleep, or fat-loss result.
Funding: Support came from the State of Ohio Eminent Scholar Program, the World Anti-Doping Agency, the Diabetes Research Initiative, ConjuChem, and two NIH grants. These facts and results were checked 21 August 2026.
What is CJC-1295 with DAC?
The first paper describes CJC-1295 as a changed form of growth hormone-releasing hormone. It has 29 amino acids (PMID 15817669). The group at its end reacts with albumin (PMID 15817669). This bond makes it act for longer.
The US FDA treats the CJC-1295 free base and DAC form as distinct active parts (American FDA CJC-1295 briefing). The human trials above used the form that binds to albumin. A vial marked CJC-1295 no DAC does not name the form used in those trials. The label does not prove what is in the vial. These identity claims were checked 21 August 2026.
Did human studies measure muscle gain, recovery, sleep, or fat loss?
No published CJC-1295 trial result for muscle gain, recovery, sleep, or fat loss was found. That is a gap in the papers searched. It does not prove that no such effect can occur.
The exact-name PubMed clinical-trial search returned two papers on 21 August 2026. They were PMID 16352683 and PMID 17018654. Both measured hormones in healthy adults.
The exact-name ClinicalTrials.gov searches returned one study on 21 August 2026. NCT00267527 was a phase 2 trial with random group assignment. It enrolled people with HIV and excess fat around their organs. The record lists an actual enrollment of 120 people (NCT00267527). ConjuChem was the sponsor. The record says the trial stopped early. It gives no reason for this. It posts no results.
What CJC side effects did human studies record?
The trials found large rises in hormone levels. They also recorded these side effects.
In the single-injection trial, 33 of 35 people given CJC-1295 reported an unwanted effect (PMID 16352683). That was 94%. Two of seven people given placebo reported an unwanted effect. That was 29%. Every event was mild or moderate. None needed medical treatment.
About 70% of people given CJC-1295 had a short-lived reaction where they were injected (PMID 16352683). Almost 30% had hives at the site (PMID 16352683). Headache occurred in 63% (PMID 16352683). Diarrhea occurred in 43% (PMID 16352683). A body-wide reaction from widened blood vessels occurred in 30% (PMID 16352683). The paper defined this as flushing, warmth, or a brief drop in blood pressure.
In Study 1, loose stools or diarrhea occurred in 45% of the 125 mcg/kg group (DOI 10.1210/jc.2005-1536; checked 2026-09-05). The 250 mcg/kg group had a rate of 100% (DOI 10.1210/jc.2005-1536; checked 2026-09-05). ConjuChem funded the trial.
Each person given the drug more than once had a mild reaction at the site (PMID 16352683). Flushing ranged from 40% after lower study injections to 100% after higher study injections (PMID 16352683). The paper also reports headache, nausea, and abdominal pain. It reports group rates of 20% to 80% for headache. It reports 20% for nausea or abdominal pain.
One person reported mild, brief leg spasms and some loss of control over movement (PMID 16352683). Two people had brief dizzy spells and low blood pressure (PMID 16352683). Two people left Study 1 after mild reactions at the site. One person left Study 2 after several mild effects. The paper found no serious side effect in either trial. It found no consistent change in lab tests or heart traces. It found no significant antibody formation.
The separate 12-man study found a dose-related rise in heart rate (PMID 17018654). It also found brief redness and skin that was sore to touch at the site. The authors found no serious side effect. Each effect they found was short-lived.
The rates describe these small trial groups. They are not rates for all current products. The other trial findings in this section were checked 21 August 2026. The Study 1 stool findings above were checked 5 September 2026. The funding for each study appears beside its measured results above.
What does one forum user report?
Mike Jason Pascual described taking a product labelled CJC-1295 without DAC together with ipamorelin. The original ExcelMale thread was opened in a browser on 21 August 2026.
So, far so good. [...] Workouts are excellent. [...] I feel a little groggy in the morning.
The omitted words give an amount and schedule. This is one self-reported and self-selected account. The post cannot tell the effects of CJC-1295 and ipamorelin apart. No lab checked the products. No payment is disclosed for the post. The link leads to the full thread.
What have CJC-1295 vial tests found?
A peer-reviewed paper tested one unknown sample sent by Norwegian authorities (PMID 21204297). It found a 29-amino-acid peptide with a terminal amide. The proposed sequence matched a peptide marketed under the CJC-1295 name. One sample cannot describe the whole market. The PubMed record lists no grant support. These details were checked 21 August 2026.
A 2026 preprint studied 6,487 reports sent in by choice. These covered 14 peptides (DOI 10.20944/preprints202604.1748.v1). It has not been peer-reviewed. In the CJC-1295 group, 22 reports failed to match the named peptide. The paper gives this rate as 9.1%. The paper does not give the full size of this group. For CJC-1295 reports that matched the named peptide, median purity was 98.49%. The middle half ranged from 91.59% to 99.60%.
The authors also applied two release models. Their compounding-style model used 90% to 110% of label amount and at least 98% purity. 29.2% of CJC-1295 reports passed both parts. Their tighter manufactured-style model used 95% to 105% of label amount and at least 99.5% purity. 10.7% passed both parts. These are the authors' comparison models. They are not official release decisions for these vials.
People and peptide companies chose which reports to submit. The sample was not drawn at random from the market. The tests checked which peptide was present. They also checked its amount and purity by chromatography. Only 243 reports across all 14 peptides included endotoxin tests. It did not show that the CJC-1295 group was sterile. The preprint reports no outside funding. Its authors said they had no conflict of interest. These preprint details were checked 21 August 2026.
The vial-testing guide explains what identity, amount, purity, endotoxin, and sterility tests answer separately.
What does EMA's central register show for CJC-1295?
Rules differ by country. EMA made its report on 22 August 2026. It held 2,731 medicine rows. No row matched CJC-1295, CJC 1295, or mod-GRF 1-29.
The search covers only EMA's central EU route. It does not cover national registers. CJC-1295's status in Europe therefore stays unclear. Checked 22 August 2026.
What does the FDA say about CJC-1295 compounding in the US?
For compounding in the US, the FDA's current safety page places CJC-1295 in its withdrawn-nominations table. It does not appear in the current Category 2 table. The row cites immune-response concerns and peptide impurities. The American agency says it identified serious events that include increased heart rate and a systemic vasodilatory reaction. This is the FDA's US risk assessment. It is not another clinical trial result.
The American FDA's staff briefing says no CJC-1295 form is a component of a drug approved by that agency. The briefing treats five nominated forms as different bulk substances. These US status claims were checked 21 August 2026.
Primary FDA sources in the US: current bulk-substance safety-risk page and American FDA CJC-1295 briefing.
How does CJC-1295 relate to other peptides?
The training and recovery hub compares human evidence across related compounds. The CJC-1295 register record keeps evidence and regulatory status separate. The ipamorelin guide covers the other compound named in the forum account.